Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Falls in Burberry, housebuilders pile pressure on FTSE

share with twitter share with LinkedIn share with facebook
share via e-mail
11/09/2017 | 06:07pm CEST
The London Stock Exchange is seen attached to the building London

LONDON (Reuters) - Heavy losses from luxury group Burberry weighed on Britain's top share index on Thursday which hit a two-week low as investors showed anxiety about the retail and housebuilding sectors.

The FTSE 100 <.FTSE> index sank 0.6 percent, slightly outperforming a sharp slump in European stocks, while mid-caps <.FTMC> dropped 1.1 percent.

Burberry (>> Burberry Group) fell 9.4 percent, its biggest one-day loss since September 2012, on the high cost of its plans to move upmarket by focusing on leather goods and fashion and cutting sales to non-luxury stores.

"Today's results were overshadowed by the strategic reset [...] which implies no sales and earnings growth in 2019 and 2020," said Berenberg luxury analysts.

"Despite the short-term downside risk to Burberry's earnings, today's strategy update left us feeling confident about the CEO's vision," they added.

Burberry's shares had gained 34 percent so far this year, outstripping the FTSE 100 which has gained just over 5 percent.

In a weak day for retailers, Sainsbury's (>> J Sainsbury) shares fell 1.8 percent after lower sales confirmed investors' fears about inflationary pressures on consumers.

"A 2 percent first-half profit beat and confirmed full-year guidance does little to change our concerns around Sainsbury's vulnerability to a weakening UK consumer outlook," said Jefferies analysts.

Marks & Spencer (>> Marks & Spencer Group) also fell 2.4 percent, while small-cap department store Debenhams (>> Debenhams Plc) sank 6.9 percent.

Housebuilders also suffered, with shares in Persimmon (>> Persimmon), Taylor Wimpey (>> Taylor Wimpey) and Barratt Developments (>> Barratt Developments) falling by 2.8 percent to 3.9 percent after a survey showed house prices in Britain were no longer rising.

Weak results added to price pressures for mid-cap builder Redrow (>> Redrow plc), which was down 6.6 percent . Bovis Homes (>> Bovis Homes Group), Crest Nicholson (>> Crest Nicholson Holdings PLC) and Bellway (>> Bellway) fell 4.9 to 5.7 percent.

"Redrow's announcement will do little to cool any jitters around market sentiment on new housing," said analysts at Davy Research.

Business media company Informa (>> Informa PLC) was the top gainer, up 4.3 percent. The company reported revenue rose in the first 10 months of 2017, buoyed by its global exhibitions business.

Outside the blue chips, a trading update weighed on Hikma (>> Hikma Pharmaceuticals), which dropped 5.5 percent after cutting its generic sales forecast again. Its partner Vectura Group (>> Vectura Group PLC) fell 7.7 percent.

Both companies are in a dispute with the U.S. Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's (>> GlaxoSmithKline) lung drug Advair in the U.S. market.

Inmarsat (>> Inmarsat) sank 9 percent after the satellite firm narrowed its guidance for full-year earnings.

(Reporting by Kit Rees, editing by Larry King and Alexander Smith)

By Kit Rees and Helen Reid

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA 2.49% 5793 Delayed Quote.10.72%
BARRATT DEVELOPMENTS 0.75% 562.2 Delayed Quote.-13.17%
BELLWAY 1.42% 3007 Delayed Quote.-15.60%
BOVIS HOMES GROUP 2.16% 1159 Delayed Quote.-1.11%
BURBERRY GROUP -0.77% 1995.5 Delayed Quote.11.36%
CREST NICHOLSON HOLDINGS PLC -1.03% 347.4 Delayed Quote.-35.27%
DEBENHAMS PLC 0.05% 9.865 Delayed Quote.-71.61%
FTSE 100 INDEX 0.28% 7234.11 End-of-day quote.-5.90%
GLAXOSMITHKLINE 0.81% 1535.2 Delayed Quote.16.08%
HIKMA PHARMACEUTICALS 1.62% 1880.5 Delayed Quote.65.83%
INFORMA PLC 0.35% 749.4 Delayed Quote.3.80%
INMARSAT -0.28% 497.6 Delayed Quote.1.67%
J SAINSBURY 0.32% 317.4 Delayed Quote.31.07%
MARKS & SPENCER GROUP 0.56% 286 Delayed Quote.-9.15%
PERSIMMON 0.93% 2381 Delayed Quote.-13.04%
REDROW PLC 2.10% 584 Delayed Quote.-12.61%
TAYLOR WIMPEY 1.72% 171.95 Delayed Quote.-16.69%
VECTURA GROUP PLC -0.06% 77.95 Delayed Quote.-33.77%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
01:15aMHEALTH APP MARKET EXPECTED TO GROW : This market research report on MHealth Ap..
09/25ASTRAZENECA : Positive Data Bolsters Case For AstraZeneca's Imfinzi -- Update
09/25ASTRAZENECA : Immunotherapy drug cuts lung cancer deaths by almost a third
09/25ASTRAZENECA : Data Show Cancer Drug Imfinzi Reduces Death Risk
09/25ASTRAZENECA : Imfinzi is the first immunotherapy to demonstrate significant over..
09/25ASTRAZENECA : IMFINZI® (durvalumab) is the First Immunotherapy to Demonstrate Si..
09/25ASTRAZENECA : Bydureon receives positive EU CHMP opinion for EXSCEL cardiovascul..
09/25ASTRAZENECA : Ships FLUMIST® QUADRIVALENT Vaccine in the US for 2018-2019 Flu Se..
09/25ASTRAZENECA : Trailing rivals, AstraZeneca offers a hit and a miss on key cardio..
More news
News from SeekingAlpha
09/25Pfizer facing difficult path to ramp up biosimilar business 
09/25ARVINAS IPO : 40% Is Cash, But Research Is At An Early Stage 
09/25AstraZeneca's Imfinzi improved survival in late-stage lung cancer study; shar.. 
09/25AstraZeneca ships FLUMIST QUADRIVALENT vaccine in the US 
09/25European advisory group backs inclusion of CV data in labeling of AstraZeneca.. 
Financials ($)
Sales 2018 22 396 M
EBIT 2018 5 404 M
Net income 2018 2 284 M
Debt 2018 14 738 M
Yield 2018 3,68%
P/E ratio 2018 40,37
P/E ratio 2019 33,97
EV / Sales 2018 4,84x
EV / Sales 2019 4,56x
Capitalization 93 622 M
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 77,4 $
Spread / Average Target 4,4%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA10.72%93 622
JOHNSON & JOHNSON2.26%376 847
PFIZER21.29%257 522
NOVARTIS-0.63%217 697
ROCHE HOLDING LTD.-5.48%209 212
MERCK AND COMPANY26.36%188 241